TNDM
Tandem Diabetes Care, Inc.22.60
+0.49+2.22%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.53BP/E (TTM)
-Basic EPS (TTM)
-3.03Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
FDA clears SteadiSet infusion set
Tandem Diabetes Care secured FDA 510(k) clearance on August 6, 2025, for its SteadiSet infusion set, enabling up to seven days of insulin delivery with a one-handed, hidden-needle inserter for type 1 diabetes patients. The company plans to launch it standalone for t:slim X2 and Tandem Mobi pumps, plus integrate it into the upcoming tubeless Mobi system, while scaling manufacturing over coming quarters. No financial details disclosed yet. Forward-looking plans hinge on regulatory and supply risks.
10-Q
Q2 FY2025 results
Tandem Diabetes Care posted solid Q2 revenue growth, with sales climbing 8.5% year-over-year to $240.7M (derived), driven by higher U.S. pump and supply volumes amid the Tandem Mobi rollout, while international sales rose 8.1% to $70.5M on supply strength despite softer pump shipments. Gross margin edged up to 52.3% from 50.8% (derived), reflecting better pricing, though operating loss widened to $51.8M from $30.8M due to $20.0M in litigation settlement costs with Roche and elevated SG&A from sales expansion. For the half-year, revenue surged 14.9% to $475.1M (derived), but net loss ballooned to $183.0M versus $73.5M last year, fueled by a $75.2M IPR&D charge for the AMF Medical revision and $6.7M lease impairments; diluted EPS fell to $(2.74) on 66,729 weighted shares, consistent with the loss position. Cash and equivalents stood at $64.1M with $251.2M in short-term investments, supporting $309.1M in long-term convertible notes due 2029 at 1.50%, while operating cash used $27.8M and free cash flow (derived) was negative $36.9M after $9.2M capex; the Roche settlement closed in May 2025 for $36.0M over four years (cash), recognizing $13.3M in licensed patents amortized over seven years. Competition from automated insulin rivals remains a key risk.
8-K
Q2 sales hit $240.7M
Tandem Diabetes Care reported Q2 2025 sales of $240.7 million, up 8% from $221.9 million last year, with U.S. revenue hitting $170.2 million and international at $70.5 million. Gross margin improved to 52%, yet operating loss widened to $51.8 million due to $20 million in litigation costs. The company guides for $1.0 billion in full-year sales, targeting 53-54% margins while advancing products like the Tandem Mobi with CE Mark. Litigation expenses dragged profitability.
IPO
Employees
Sector
Industry
BBNX
Beta Bionics, Inc.
29.63-0.09
DXCM
DexCom, Inc.
66.37+0.64
EMBC
Embecta Corp.
11.89-0.04
GCTK
GlucoTrack, Inc.
5.18+0.03
MDT
Medtronic plc.
97.72-0.85
MODD
Modular Medical, Inc.
0.34-0.03
PODD
Insulet Corporation
288.73-2.78
SENS
Senseonics Holdings, Inc.
6.62-0.17
STME
Stimcell Energetics, Inc.
0.37-0.04
TCMD
Tactile Systems Technology, Inc
28.95+0.52